Norwegian biotechnology company Clavis Pharma was spun out of Norsk Hydro in August 2001 to commercialize Lipid Vector Technology (LVT). LVT conjugates fatty acids to existing therapeutics to improve their ability to enter target cells. Clavis' first product is an LVT derivative of Ara-C, a common chemotherapy for blood cancers, which the firm is testing in solid tumor indications.

Sympore aims to develop new, improved versions of both existing medicines as well as novel drugs by elucidating and harnessing the natural mechanisms that underlie directed transport in the body.